Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UPSTREAM biomarker-driven treatment strategy in recurrent/metastatic head and neck squamous cell carcinoma
2017-000086-74Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab, monalizumab, palbociclib, niraparib, afatinib and 11 more in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Efficacy by patient cohort. Started Jun 2017; status: completed.
02
Drugs
durvalumabmonalizumabpalbociclibniraparibafatinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2017-000086-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000086-74.